MK-3682 (225 mg)

3 trials

Sponsors

Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc

Conditions

Chronic Hepatitis C infected patientChronic hepatitis C infected patient MedDRA version: 20.0 Level: LLT Classification code 10019751 Term: Hepatitis C virus System Organ Class: 100000004848Hepatitis C infection

Phase 2

MK-5172/MK-3682 with MK-8742 or MK-8408 in HCV GT1 and GT2 Infected Subjects.

Active, not recruitingEUCTR2014-003304-73-SE

Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.Chronic Hepatitis C infected patient

Start: 2015-01-21Target: 465Updated: 2017-12-11

MK-5172/MK-3682 with MK-8742 or MK-8408 in HCV GT3, GT4, GT5 and GT6 Infected Subjects.

Active, not recruitingEUCTR2014-003347-35-DK

Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.Chronic hepatitis C infected patient MedDRA version: 20.0 Level: LLT Classification code 10019751 Term: Hepatitis C virus System Organ Class: 100000004848

Start: 2014-10-30Target: 500Updated: 2017-07-03

MK-3682B (MK-5172 + MK-3682 + MK-8408 Fixed Dose Combination (FDC)) in HCV GT1 or GT3 DAA Failures

Active, not recruitingEUCTR2015-001483-19-SE

Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., IncHepatitis C infection

Start: 2016-01-12Target: 200Updated: 2018-04-30